Clinical trials: Melanoma, Stage I
Recurrent Melanoma, Stage IA Skin Melanoma
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01989559
- Testing
- gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma (Skin)
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help…
- Trial name
- NCT00897546
- Testing
- laboratory biomarker analysis
- Volunteers
- 1,716 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
This study is a phase I clinical trial aimed to determine the recommended dose of [131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma (binding [131I]ICF01012 ).
- Trial name
- MELRIV-1 (NCT03784625)
- Testing
- [131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2), [131I]ICF01012 (therapeutic dose level 3)
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Centre Jean Perrin
Head and Neck Cancer, Parotid Gland Cancer
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
- Conditions
- Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma
- Trial name
- NCT00405405
- Testing
- Cisplatin, Docetaxel, Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00003665
- Testing
- dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT02498665
- Testing
- DSP-7888 Dosing Emulsion
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Metastatic Melanoma
Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
This study evaluates the safety as well as the potential clinical efficacy of an adoptive transfer of CD8+ T cells, sorted with HLA-peptide multimers and specific for Melan-A and MELOE-1 melanoma antigens, to patients suffering…
- Trial name
- MelSort (NCT02424916)
- Testing
- Melanoma antigens-specific CD8+ T lymphocytes
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Nantes University Hospital
Advanced Melanoma
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine
This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense
- Trial name
- NCT00542893
- Testing
- Genasense® (G3139, oblimersen sodium), Genasense followed by DTIC; then DTIC alone, DTIC alone; then Genasense followed by DTIC
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genta Incorporated
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
- Trial name
- NCT06839105
- Testing
- Taxol, Cisplatin or Carboplatin, Pemetrexed
- Where
- 13 sites in China
- Volunteers
- 214 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Breast Cancer, Brain Cancer
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors.
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers
- Trial name
- NCT02045368
- Testing
- IGF-Methotrexate conjugate
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- IGF Oncology, LLC
Melanoma
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
This is a single center, open phase I dose escalation study. This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV…
- Trial name
- NCT01672450
- Testing
- Intratumoral Ipilimumab and Interleukin-2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for…
- Trial name
- NCT04261439
- Testing
- NIZ985, Spartalizumab, Tislelizumab
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
This open-label, multicenter study will evaluate the pharmacokinetics, safety and efficacy of vemurafenib in Chinese participants with BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Trial name
- NCT01910181
- Testing
- Vemurafenib
- Where
- 2 sites in China
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma.
- Trial name
- NCT00791271
- Testing
- Decitabine, Pegylated Interferon Alpha-2b
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma
RATIONALE: Diagnostic procedures may improve the ability to detect the presence or recurrence of disease. PURPOSE: Diagnostic trial to detect melanoma markers in the lymph nodes or peripheral blood of patients who have melanoma.
- Trial name
- NCT00004153
- Testing
- reverse transcriptase-polymerase chain reaction, sentinel lymph node biopsy
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Chicago